Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ad26 Mos4 HIV tetravalent vaccine - Janssen Vaccines and Prevention B.V

Next Previous
Drug Profile

Ad26 Mos4 HIV tetravalent vaccine - Janssen Vaccines and Prevention B.V

Alternative Names: Ad26.Mos.1.Env + Ad26.Mos.2S.Env + Ad26.Mos1.Gag-Pol + Ad26.Mos2.Gag-Pol; Ad26.Mos4.HIV; Adenovirus serotype-26 mosaic-4 HIV vaccine; Adenovirus serotype-26 mosaic-4 human immunodeficiency virus vaccine; Tetravalent Ad26 Mos HIV; VAC 89220

Latest Information Update: 16 Jan 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Crucell Holland
  • Developer Beth Israel Deaconess Medical Center; Janssen Vaccines and Prevention B.V
  • Class AIDS vaccines; DNA vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III HIV infections
  • Phase I/II Immunodeficiency disorders; Immunological disorders; Retrovirus infections; Sexually transmitted infections

Most Recent Events

  • 12 Jan 2024 US Army Medical Research and Development Command and Janssen Vaccines and Prevention plans a phase I trial for HIV infection (Prevention) in January 2024 in Uganda (IM) (NCT06205056)
  • 10 Aug 2023 Janssen Vaccines & Prevention B.V. completes a phase III trial in HIV infections (Prevention) in Poland, Puerto Rico, Peru, Mexico, Italy, Brazil, Argentina, Spain, USA (IM) (NCT03964415) (EudraCT2018-003666-13)
  • 18 Jan 2023 Efficacy and adverse events data from a phase III MOSAICO trial in HIV infections (Prevention) released by Janssen Vaccines and Prevention B.V
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top